Abstract:For the majority of pediatric patients with soft tissue tumors, some form of selective systemic therapy is required. Here we show that bone marrow-derived non-hematopoietic mesenchymal stem cells (MSCs) integrate into pediatrics soft tissue sarcoma xenografts as stromal fibroblasts. Importantly, exogenously administered MSC preferentially engraft at the sites of disseminated tumor nodules throughout the body. These findings suggest the development of novel anti-cancer therapies based on the local production of biological agents by gene manipulated MSC. We show that human MSC can be effectively transduced with adenovirus type 5-based vectors and with vectors based on adeno-associated virus (AAV). The majority of AAV serotypes tested (AAV1/6, 2, 3, 4, 5, and 8) are capable of transducing hMSC, albeit with relatively low efficiencies. Vector modifications to the AAV capsid, such as the inclusion of the RGD-tripeptide motif in capsids of either AAV1 or AAV2-based vectors, or modification of the vector genome to generate "double-stranded", or "self-complementary" AAV vectors, both lead to significant increases in AAV-mediated hMSC gene transduction. Here, we examined whether hMSC producing human TNF-related apoptosis inducing ligand (hTRAIL) (hTRAIL-MSC) can inhibit the growth of subcutaneous human Ewing's Sarcoma xenografts in nude mice. MSC were transduced with an hTRAIL expressing adenovirus, or AAV vector. These hTRAIL-MSC produced hTRAIL and could directly induce apoptosis of A673 Ewing's sarcoma cells in co-culture experiments in vitro. When co-injected with A673 sarcoma cells into the flanks of nude mice (1:2 ratio of hMSC to A673 sarcoma cells), all treated animals failed to develop tumors (n=5). Control animals co-injected with eGFP-MSC (Ad-eGFP transduced hMSC) and A673 sarcoma cells (n=5), or A673 sarcoma cells alone (n=10) all developed tumors. We then injected hTRAIL-MSC intravenously (IV) (single dose of 5 105 MSC) into nude mice bearing established subcutaneous A673 tumors; tumor growth was inhibited approximately 30% as compared to untreated controls, and as compared to controls treated with eGFP-MSC (n=5) (p=0.01). Immunohistochemical analysis of hTRAIL-MSC treated animals showed engraftment and differentiation of hMSC into myofibroblast-like tumor-associated stroma cells. IV injected hTRAIL-MSC prolonged the survival of mice bearing A673 Ewing sarcoma grafts as compared to untreated animals, or control (eGFP-MSC) treated animals. These data suggest that IV administered gene-modified MSC can inhibit the growth of pediatric soft tissue sarcomas. Importantly, the antitumor effects were only achieved when MSC were integrated into the tumor microenvironment, but not when MSC were injected subcutaneously into the opposite flank. Therefore, tumor inhibition required spatial proximity of MSC to the malignant cells. These findings suggest that TRAIL can serve as a direct inhibitor of tumor proliferation and suggest the use of gene-manipulated MSC for pediatric cancer therapy.

Suppression of orthotopically implanted hepatocarcinoma in mice by umbilical cord-derived mesenchymal stem cells with sTRAIL gene expression driven by AFP promoter

The Therapeutic Potential of Adipose Tissue-Derived Mesenchymal Stem Cells to Enhance Radiotherapy Effects on Hepatocellular Carcinoma.

Committed-differentiation of Transplanted Bone Derived Mesenchymal Stem Cells and Their Potential to Amend Damaged Liver Functions: in Vivo Experiment with Mice

Pretreatment of Umbilical Cord Derived MSCs with IFN-γ and TNF-α Enhances the Tumor-Suppressive Effect on Acute Myeloid Leukemia.

Human umbilical cord matrix stem cells efficiently rescue acute liver failure through paracrine effects rather than hepatic differentiation.

Human mesenchymal stem cells overexpressing pigment epithelium-derived factor inhibit hepatocellular carcinoma in nude mice

Bone Marrow Mesenchymal Stem Cells Exhibit a Transdifferentiation and Therapeutic Effects in a Murine Model of Orthotopic Hepatocellular Carcinoma.

Human Menstrual Blood-Derived Mesenchymal Stem Cells As a Cellular Vehicle for Malignant Glioma Gene Therapy

Human Umbilical Cord Mesenchymal Stem Cells Inhibit Liver Fibrosis Via the Microrna-148A-5p/slit3 Axis

Surface expression of anti-CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A-engineered human umbilical cord mesenchymal stem cells

Early Homing Behavior of Stro-1− Mesenchyme-Like Cells Derived from Human Embryonic Stem Cells in an Immunocompetent Xenogeneic Animal Model

Secreted TRAIL gene‐modified adipose‐derived stem cells exhibited potent tumor‐suppressive effect in hepatocellular carcinoma cells

Effect of Bone-Marrow-derived Mesenchymal Stem Cells on High-Potential Hepatocellular Carcinoma in Mouse Models: an Intervention Study

E1a-Engineered Human Umbilical Cord Mesenchymal Stem Cells As Carriers and Amplifiers for Adenovirus Suppress Hepatocarcinoma in Mice

Therapeutic efficacy and in vivo distribution of human umbilical cord-derived mesenchymal stem cell spheroids transplanted via B-Ultrasound-guided percutaneous portal vein puncture in rhesus monkey models of liver fibrosis

Human Mesenchymal Stem Cells Inhibit Metastasis of a Hepatocellular Carcinoma Model Using the MHCC97‐H Cell Line

Pre-activated human mesenchymal stromal cells in combination with doxorubicin synergistically enhance tumor-suppressive activity in mice

Ultrasound-targeted microbubble destruction optimized HGF-overexpressing bone marrow stem cells to repair fibrotic liver in rats

74. Specific Delivery of hTRAIL and Inhibition of Ewing's Sarcoma Growth by Transplantation of Viral Vector-Transduced Bone Marrow-Derived Mesenchymal Stem Cells (MSC)

Enhanced anti-tumor efficacy with multi-transgene armed mesenchymal stem cells for treating peritoneal carcinomatosis

Genetically Engineered Bone Marrow-Derived Mesenchymal Stem Cells Co-Expressing IFN-γ and IL-10 Inhibit Hepatocellular Carcinoma by Modulating MAPK Pathway.